Integra LifeSciences Holdings Corporation (NASDAQ:IART) Given Consensus Rating of “Reduce” by Analysts

Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) have been given an average recommendation of “Reduce” by the seven analysts that are currently covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $14.80.

Several equities analysts have recently weighed in on IART shares. Wall Street Zen raised Integra LifeSciences from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Wells Fargo & Company decreased their price objective on shares of Integra LifeSciences from $13.00 to $12.00 and set an “equal weight” rating for the company in a research note on Friday. Truist Financial reiterated a “hold” rating and issued a $13.00 price target (down from $15.00) on shares of Integra LifeSciences in a report on Monday, November 3rd. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Integra LifeSciences in a research report on Monday, December 29th.

Institutional Trading of Integra LifeSciences

A number of large investors have recently modified their holdings of IART. Global Retirement Partners LLC bought a new stake in Integra LifeSciences during the 4th quarter valued at $25,000. GAMMA Investing LLC increased its stake in shares of Integra LifeSciences by 55.3% during the third quarter. GAMMA Investing LLC now owns 2,565 shares of the life sciences company’s stock valued at $37,000 after buying an additional 913 shares during the period. Osaic Holdings Inc. raised its holdings in shares of Integra LifeSciences by 36.6% in the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock valued at $51,000 after acquiring an additional 1,104 shares in the last quarter. AlphaQuest LLC purchased a new stake in Integra LifeSciences in the second quarter worth about $73,000. Finally, EMC Capital Management bought a new position in Integra LifeSciences during the 2nd quarter worth about $75,000. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Stock Performance

Shares of NASDAQ:IART opened at $11.08 on Monday. The firm has a fifty day simple moving average of $11.96 and a two-hundred day simple moving average of $13.18. Integra LifeSciences has a 52 week low of $10.60 and a 52 week high of $24.36. The company has a quick ratio of 1.46, a current ratio of 2.54 and a debt-to-equity ratio of 1.66. The stock has a market capitalization of $863.10 million, a P/E ratio of -1.66 and a beta of 1.02.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings results on Thursday, February 26th. The life sciences company reported $0.83 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.04. Integra LifeSciences had a negative net margin of 31.58% and a positive return on equity of 14.76%. The firm had revenue of $434.93 million during the quarter, compared to the consensus estimate of $429.62 million. During the same quarter last year, the firm earned $0.97 EPS. The firm’s revenue for the quarter was down 1.7% compared to the same quarter last year. Integra LifeSciences has set its Q1 2026 guidance at 0.370-0.450 EPS and its FY 2026 guidance at 2.300-2.400 EPS. On average, analysts expect that Integra LifeSciences will post 2.45 earnings per share for the current fiscal year.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.